Articles Tagged With: carbapenems
-
Clostridioides difficile: Risk Factors for Disease
Approximately one-tenth of asymptomatic patients with Clostridioides difficile colonization went on to develop disease. A wide range of antibiotic exposures represent a significant risk.
-
Monotherapy of Pseudomonas aeruginosa Bacteremia — Which β-Lactam Antibiotic Is Best?
No significant difference in the mortality of patients with Pseudomonas aeruginosa bacteremia was seen regardless of treatment with a carbapenem, ceftazidime, or piperacillin-tazobactam. However, the emergence of resistance occurred significantly more frequently in those treated with a carbapenem — largely related to imipenem use.
-
Meropenem vs. Piperacillin-tazobactam for Bacteremia Due to ESBL-Producers: The MERINO Trial
In an open-label, randomized, noninferiority trial evaluating the efficacy of piperacillin-tazobactam vs. meropenem for definitive therapy in treating bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae, piperacillin-tazobactam therapy did not result in noninferior 30-day, all-cause mortality compared to meropenem. Investigators stopped the trial early due to futility.